

## **Publicacions 2014**

### **Preventive treatments for breast cancer: recent developments.**

Alés-Martínez JE, Ruiz A, Chacón JI, Lluch Hernández A, Ramos M, Córdoba O, Aguirre E, Barnadas A, Jara C, González S, Plazaola A, Florián J, Andrés R, Sánchez Rovira P, Frau A.

Clin Transl Oncol. 2014 Dec 2. [Epub ahead of print]

### **Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs.**

Tibau A, Bedard PL, Srikanthan A, Ethier JL, Vera-Badillo FE, Templeton AJ, Ocaña A, Seruga B, Barnadas A, Amir E.

J Clin Oncol. 2015 Jan 1;33(1):100-6. doi: 10.1200/JCO.2014.57.8898. Epub 2014 Nov 10.

### **Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.**

Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.

Neoplasia. 2014 Oct 23;16(10):861-7. doi: 10.1016/j.neo.2014.08.012. eCollection 2014 Oct.

### **Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).**

Barnadas A, Manso L, de la Piedra C, Meseguer C, Crespo C, Gómez P, Calvo L, Martínez P, Ruiz-Borrego M, Perelló A, Antón A, Codes M, Margelí M, Murias A, Salvador J, Seguí MÁ, de Juan A, Gavilá J, Luque M, Pérez D, Zamora P, Arizcuma A, Chacón JI, Heras L, Martín-Fernández M, Mahillo-Fernández I, Tusquets I.

Bone. 2014 Nov;68:32-40. doi: 10.1016/j.bone.2014.07.036. Epub 2014 Aug 7.

### **Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.**

Sullivan I, Salazar J, Majem M, Pallarés C, Del Río E, Páez D, Baiget M, Barnadas A.

Cancer Lett. 2014 Oct 28;353(2):160-6. doi: 10.1016/j.canlet.2014.07.023. Epub 2014 Jul 25.

**EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer.**

Sebio A, Salazar J, Páez D, Berenguer-Llergo A, Del Río E, Tobeña M, Martín-Richard M, Sullivan I, Targarona E, Balart J, Baiget M, Barnadas A.

Pharmacogenomics J. 2014 Jul 15. doi: 10.1038/tpj.2014.33. [Epub ahead of print]

**Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.**

Peiró G, Ortiz-Martínez F, Gallardo A, Pérez-Balaguer A, Sánchez-Payá J, Ponce JJ, Tibau A, López-Vilaro L, Escuin D, Adrover E, Barnadas A, Lerma E.

Br J Cancer. 2014 Aug 12;111(4):689-95. doi: 10.1038/bjc.2014.327. Epub 2014 Jun 17.

**Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.**

Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez-Rovira P, Ramos M, Rojo F, Burgués O, Carrasco E, Caballero R, Porrás I, Tibau A, Cámara MC, Lluch A.

Br J Cancer. 2014 Mar 4;110(5):1139-47. doi: 10.1038/bjc.2013.831. Epub 2014 Jan 23.

**Efficacy of erlotinib in patients with relapsed glioblastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.**

Gallego O, Cuatrecasas M, Benavides M, Segura PP, Berrocal A, Erill N, Colomer A, Quintana MJ, Balaña C, Gil M, Gallardo A, Murata P, Barnadas A.

J Neurooncol. 2014 Jan;116(2):413-9. doi: 10.1007/s11060-013-1316-y. Epub 2013 Dec 19.

**Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.**

Sebio A, Páez D, Salazar J, Berenguer-Llargo A, Paré-Brunet L, Lasa A, Del Río E, Tobeña M, Martín-Richard M, Baiget M, Barnadas A.

Pharmacogenomics J. 2014 Jun;14(3):256-62. doi: 10.1038/tpj.2013.29. Epub 2013 Aug 20.

**Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study.**

Balaña C, Gil MJ, Perez P, Reynes G, Gallego O, Ribalta T, Capellades J, Gonzalez S, Verger E.

Target Oncol. 2014 Dec;9(4):321-9. doi: 10.1007/s11523-014-0305-1. Epub 2014 Jan 15.

**A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.**

Reynés G, Balaña C, Gallego O, Iglesias L, Pérez P, García JL

Anticancer Drugs. 2014 Jul;25(6):717-22. doi: 10.1097/CAD.000000000000059.

**Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.**

Martín-Liberal J, López-Pousa A, Broto JM, Cubedo R, Gallego O, Brendel E, Tirado OM, del Muro XG.

Invest New Drugs. 2014 Apr;32(2):287-94. doi: 10.1007/s10637-013-9989-9. Epub 2013 Jun 26

**Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer.**

De Liaño AG, Reig O, Mellado B, Martin C, Rull EU, Maroto JP.

Br J Cancer. 2014 Apr 29;110(9):2201-8. doi: 10.1038/bjc.2014.189. Epub 2014 Apr 10.

**Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.**

León X, Agüero A, López M, García J, Farré N, López-Pousa A, Quer M.

Auris Nasus Larynx. 2014 Nov 13. pii: S0385-8146(14)00171-0. doi: 10.1016/j.anl.2014.10.002. [Epub ahead of print]

**Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.**

Alamo P, Gallardo A, Di Nicolantonio F, Pavón MA, Casanova I, Trias M, Mangues MA, Lopez-Pousa A, Villaverde A, Vázquez E, Bardelli A, Céspedes MV, Mangues R.

FASEB J. 2014 Oct 30. pii: fj.14-262303. [Epub ahead of print]

**Differences between en bloc resection and enucleation of retroperitoneal sarcomas.**

Gonzalez Lopez JA, Artigas Raventós V, Rodríguez Blanco M, Lopez-Pousa A, Bague S, Abellán M, Trias Folch M.

Cir Esp. 2014 Oct;92(8):525-31. doi: 10.1016/j.ciresp.2014.02.002. Epub 2014 Apr 13.

**A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.**

Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Ann Oncol. 2014 Jan;25(1):216-25. doi: 10.1093/annonc/mdt461. Epub 2013 Nov 19.

**MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.**

Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez-Serra A, Lopez-Pousa A, Gronchi A.

Mol Cancer Ther. 2014 Jan;13(1):249-59. doi: 10.1158/1535-7163.MCT-13-0406. Epub 2013 Oct 21.

**Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.**

Martín-Liberal J, López-Pousa A, Broto JM, Cubedo R, Gallego O, Brendel E, Tirado OM, del Muro XG.

Invest New Drugs. 2014 Apr;32(2):287-94. doi: 10.1007/s10637-013-9989-9. Epub 2013 Jun 26.

**Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.**

Vidal J, Clavé S, de Muga S, González I, Pijuan L, Gimeno J, Remón J, Reguart N, Viñolas N, Gironés R, Bernet L, Majem M, Bosch-Barrera J, Porta R, Alonso N, Palmero R, Taus A, Albanell J, Espinet B, Salido M, Arriola E.

JThorac Oncol. 2014 Dec;9(12):1816-20. doi: 10.1097/JTO.0000000000000361.

**Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.**

Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.

Ann Oncol. 2014 Nov;25(11):2147-55. doi: 10.1093/annonc/mdu389. Epub 2014 Aug 27.

**Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.**

Remon J, Morán T, Reguart N, Majem M, Carcereny E, Lianes P.

Cancer Treat Rev. 2014 Jul;40(6):723-9. doi: 10.1016/j.ctrv.2014.03.006. Epub 2014 Apr 12. Review.

**Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.**

Molina-Vila MA, Bertran-Alamillo J, Gascó A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto AG, Cardona AF, Vergnenègre A, Majem M, Massuti B, Morán T, Carcereny E, Viteri S, Rosell R.

Clin Cancer Res. 2014 Sep 1;20(17):4647-59. doi: 10.1158/1078-0432.CCR-13-2391. Epub 2014 Apr 2.

**Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.**

Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.

**The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.**

Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R.

Clin Cancer Res. 2014 Apr 1;20(7):2001-10. doi: 10.1158/1078-0432.CCR-13-2233. Epub 2014 Feb 3.

**Lung cancer in women: an overview with special focus on Spanish women.**

Remon J, Molina-Montes E, Majem M, Lianes P, Isla D, Garrido P, Felip E, Viñolas N, de Castro J, Artal A, Sánchez MJ.

Clin Transl Oncol. 2014 Jun;16(6):517-28. doi: 10.1007/s12094-013-1137-7. Epub 2013 Nov 26. Review.

**Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.**

Remon J, Morán T, Majem M, Reguart N, Dalmau E, Márquez-Medina D, Lianes P.

Cancer Treat Rev. 2014 Feb;40(1):93-101. doi: 10.1016/j.ctrv.2013.06.002. Epub 2013 Jul 3. Review.

**Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base.**

Girones R, Aparicio J, Roure P, Germa-Lluch JR, García Del Muro X, Vazquez-Estevez S, Saenz A, Sastre J, Arranz Arija J, Gallardo E, Gonzalez-Billalabeitia E, Sanchez-Hernandez A, Terrasa J, Hernandez A, Santander C, Cillan E, Sagastibelza N, Almenar-Cubells D, Lopez Brea M, **Maroto JP**; Spanish Germ Cell Cancer Group (SGCCG).

Clin Transl Oncol. 2014 Nov;16(11):959-65. doi: 10.1007/s12094-014-1179-5. Epub 2014 Apr 10.

**Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen.**

Castellano DE, Bellmunt J, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suarez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J.

Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26.

**Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation.**

Schmidt S, Riel R, Frances A, Lorente Garin JA, Bonfill X, Martinez-Zapata MJ, Morales Suarez-Varela M, dela Cruz J, Emparanza JI, Sánchez MJ, Zamora J, Goñi JM, Alonso J, Ferrer M; EMPARO-CU Study Group.

Health Qual Life Outcomes. 2014 Feb 15;12:20. doi: 10.1186/1477-7525-12-20.

**Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma.**

Carr R, Fanti S, Paez D, Cerci J, Györke T, Redondo F, Morris TP, Meneghetti C, Auewarakul C, Nair R, Gorospe C, Chung JK, Kuzu I, Celli M, Gujral S, Padua RA, Dondi M; IAEA Lymphoma Study Group.

J Nucl Med. 2014 Dec;55(12):1936-44. doi: 10.2967/jnumed.114.145326.

**Results from Colombia's 2014 Report Card on Physical Activity for Children and Youth.**

González SA, Sarmiento OL, Cohen DD, Camargo DM, Correa JE, Páez DC, Ramírez-Vélez R.

J Phys Act Health. 2014 May;11 Suppl 1:S33-44. doi: 10.1123/jpah.2014-0170.

**Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.**

Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paez D, Loupakis F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2014 Oct 7. doi: 10.1038/tpj.2014.58.

**Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma.**

Cerci JJ, Györke T, Fanti S, Paez D, Meneghetti JC, Redondo F, Celli M, Auewarakul C, Rangarajan V, Gujral S, Gorospe C, Campo MV, Chung JK, Morris TP, Dondi M, Carr R; IAEA Lymphoma Study Group.

J Nucl Med. 2014 Oct;55(10):1591-7. doi: 10.2967/jnumed.113.134486. Epub 2014 Sep 11.

**Detection of post-exercise stunning by early gated SPECT myocardial perfusion imaging: results from the IAEA multi-center study.**

Mut F, Giubbini R, Vitola J, Lusa L, Sobic-Saranovic D, Peix A, Bertagna F, Hang Bui D, Cunha C, Obaldo J, Rodella C, Camoni L, Paez D, Dondi M.

J Nucl Cardiol. 2014 Dec;21(6):1168-76. doi: 10.1007/s12350-014-9983-4. Epub 2014 Sep 12.

**Flow dimensions on daily activities with the Spanish version of the Flow Scale (DFS).**

Rufi S, Javaloy F, Batista-Foguet JM, Solanas A, Páez D.

Span J Psychol. 2014 Jan;17:E30. doi: 10.1017/sjp.2014.34.



**FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.**

Geva R, Vecchione L, Kalogeras KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.

Gut. 2014 Jul 10. pii: gutjnl-2014-307234. doi: 10.1136/gutjnl-2014-307234.

**Interferon-alpha-induced sarcoidosis in a patient being treated for hepatitis C.**

Trien R, Cooper CJ, Paez D, Colon E, Ajmal S, Salameh H.

Am J Case Rep. 2014 May 28;15:235-8. doi: 10.12659/AJCR.890180. eCollection 2014.

**Nuclear medicine in the management of patients with heart failure: guidance from an expert panel of the International Atomic Energy Agency (IAEA).**

Peix A, Mesquita CT, Paez D, Pereira CC, Felix R, Gutierrez C, Jaimovich R, Ianni BM, Soares J Jr, Olaya P, Rodriguez MV, Flotats A, Giubbini R, Travin M, Garcia EV.

Nucl Med Commun. 2014 Aug;35(8):818-23. doi: 10.1097/MNM.000000000000143.

**The effect of the UGT1A1\*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.**

Dias MM, Pignon JP, Karapetis CS, Boige V, Glimelius B, Kweekel DM, Lara PN, Laurent-Puig P, Martinez-Balibrea E, Páez D, Punt CJ, Redman MW, Toffoli G, Wadelius M, McKinnon RA, Sorich MJ.

Pharmacogenomics J. 2014 Oct;14(5):424-31. doi: 10.1038/tpj.2014.16. Epub 2014 Apr 8.

**Incidence of new onset atrial fibrillation in patients with permanent pacemakers and the relation to the pacing mode.**

Said S, Cooper CJ, Alkhateeb H, Gosavi S, Dwivedi A, Onate E, Paez D, Abedin Z.

Med Sci Monit. 2014 Feb 18;20:268-73. doi: 10.12659/MSM.890052.

**Heritable variation in host tolerance and resistance inferred from a wild host-parasite system.**

Mazé-Guilmo E, Loot G, Páez DJ, Lefèvre T, Blanchet S.

Proc Biol Sci. 2014 Jan 29;281(1779):20132567. doi: 10.1098/rspb.2013.2567. Print 2014 Mar 22.

**Association of common gene variants in the WNT/ $\beta$ -catenin pathway with colon cancer recurrence.**

Páez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhanim L, Kahn M, Lenz F, Lenz C, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):142-50. doi: 10.1038/tpj.2013.20. Epub 2013 Jul 2.

**Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.**

Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):135-41. doi: 10.1038/tpj.2013.21. Epub 2013 Jun 11.

**Apoptosis for prediction of radiotherapy late toxicity: lymphocyte subset sensitivity and potential effect of TP53 Arg72Pro polymorphism.**

Fuentes-Raspall MJ, Caragol I, Alonso C, Ramón Y Cajal T, Fisas D, Seoane A, Carvajal N, Bonache S, Díez O, Gutiérrez-Enríquez S.

Apoptosis. 2014 Nov 15.

**Prevalence of germline MUTYH mutations among Lynch-like syndrome patients.**

Castillejo A, Vargas G, Castillejo MI, Navarro M, Barberá VM, González S, Hernández-Illán E, Brunet J, Ramón y Cajal T, Balmaña J, Oltra S, Iglesias S, Velasco A, Solanes A, Campos O, Sánchez Heras AB, Gallego J, Carrasco E, González Juan D, Segura A, Chirivella I, Juan MJ, Tena I, Lázaro C, Blanco I, Pineda M, Capellá G, Soto JL.

Eur J Cancer. 2014 Sep;50(13):2241-50. doi: 10.1016/j.ejca.2014.05.022. Epub 2014 Jun 18.

**DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.**

Osorio A, Milne RL, Kuchenbaecker K, Vaclová T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Díez O, Ramón Y Cajal T, Konstantopoulou I, Martínez-Bouzas C, Andrés Conejero R, Soucy P, McGuffog L, Barrowdale D, Lee A, Swe-Brca, Arver B, Rantala J, Loman N, Ehrencrona H, Olopade OI, Beattie MS, Domchek SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C, Lester J, John EM, Whittemore AS, Daly MB, Southey M, Hopper J, Terry MB, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Ejlertsen B, Gerdes AM, Infante M, Herráez B, Moreno LT, Weitzel JN, Herzog J, Weeman K, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Bonanni B, Mariette F, Volorio S, Viel A, Varesco L, Papi L, Ottini L, Tibiletti MG, Radice P, Yannoukakos D, Garber J, Ellis S, Frost D, Platte R, Fineberg E, Evans G, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Eccles D, Cook J, Hodgson S, Brewer C, Tischkowitz M, Douglas F, Porteous M, Side L, Walker L, Morrison P, Donaldson A, Kennedy J, Foo C, Godwin AK, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Damiola F, Poppe B, Claes K, Piedmonte M, Tucker K, Backes F, Rodríguez G, Brewster W, Wakeley K, Rutherford T, Caldés T, Nevanlinna H, Aittomäki K, Rookus MA, van Os TA, van der Kolk L, de Lange JL, Meijers-Heijboer HE, van der Hout AH, van Asperen CJ, Gómez Garcia EB, Hoogerbrugge N, Collée JM, van Deurzen CH, van der Luijt RB, Devilee P, Hebon, Olah E, Lázaro C, Teulé A, Menéndez M, Jakubowska A, Cybulski C, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Johannsson OT, Maugard C, Montagna M, Tognazzo S, Teixeira MR, Healey S, Investigators K, Olswold C, Guidugli L, Lindor N, Slager S, Szabo CI, Vijai J, Robson M, Kauff N, Zhang L, Rau-Murthy R, Fink-Retter A, Singer CF, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea MK, Berger A, Phelan CM, Greene MH, Mai PL, Lejbkowitz F, Andrulis I, Mulligan AM, Glendon G, Toland AE, Bojesen A, Pedersen IS, Sunde L, Thomassen M, Kruse TA, Jensen UB, Friedman E, Laitman Y, Shimon SP, Simard J, Easton DF, Offit K, Couch FJ, Chenevix-Trench G, Antoniou AC, Benitez J.

PLoS Genet. 2014 Apr 3;10(4):e1004256. doi: 10.1371/journal.pgen.1004256. eCollection 2014 Apr.

**Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.**

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeny LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderma-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Arden-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA.

Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15.

**About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.**

Gutiérrez-Enríquez S, Bonache S, de Garibay GR, Osorio A, Santamariña M, Ramón y Cajal T, Esteban-Cardenosa E, Tenés A, Yanowsky K, Barroso A, Montalban G, Blanco A, Cornet M, Gadea N, Infante M, Caldés T, Díaz-Rubio E, Balmaña J, Lasa A, Vega A, Benítez J, de la Hoya M, Diez O.

Int J Cancer. 2014 May 1;134(9):2088-97.

**Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).**

Andrés R, Pajares I, Balmaña J, Lloret G, Ramón Y Cajal T, Chirivella I, Aguirre E, Robles L, Lastra E, Pérez-Segura P, Bosch N, Yagüe C, Lerma E, Godino J, Miramar MD, Moros M, Astier P, Saez B, Vidal MJ, Arcusa A, Ramón y Cajal S, Calvo MT, Tres A.

Clin Transl Oncol. 2014 Mar;16(3):280-4. doi: 10.1007/s12094-013-1070-9. Epub 2013 Aug 27.

**Identification of a founder EPCAM deletion in Spanish Lynch syndrome families.**

Mur P, Pineda M, Romero A, Del Valle J, Borràs E, Canal A, Navarro M, Brunet J, Rueda D, Ramón Y Cajal T, Lázaro C, Caldés T, Blanco I, Soto JL, Capellá G.

Clin Genet. 2014 Mar;85(3):260-6. doi: 10.1111/cge.12152. Epub 2013 Apr 26.

**Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer.**

Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz H.

Ann Oncol. 2014 Nov 18. pii: mdu542.

**Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.**

Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ.

Pharmacogenet Genomics. 2014 Dec;24(12):588-96. doi: 10.1097/FPC.0000000000000091.

**Panitumumab safety for treating colorectal cancer.**

Stremitzer S, Sebio A, Stintzing S, Lenz HJ.

Expert Opin Drug Saf. 2014 Jun;13(6):843-51. doi: 10.1517/14740338.2014.915024. Epub 2014 Apr 28. Review.

**The potential of targeting Wnt/ $\beta$ -catenin in colon cancer.**

Sebio A, Kahn M, Lenz HJ.

Expert Opin Ther Targets. 2014 Jun;18(6):611-5. doi: 10.1517/14728222.2014.906580. Epub 2014 Apr 5.

**Panitumumab : leading to better overall survival in metastatic colorectal cancer?**

Sebio A, Stintzing S, Stremitzer S, Zhang W, Lenz HJ.

Expert Opin Biol Ther. 2014 Apr;14(4):535-48. doi: 10.1517/14712598.2014.894502. Epub 2014 Mar 5. Review.

**Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment.**

Vera-Badillo FE, Ocana A, Templeton AJ, Tibau A, Amir E, Tannock IF.

J Clin Oncol. 2014 Oct 1;32(28):3197. doi: 10.1200/JCO.2014.56.2447. Epub 2014 Aug 4.

**Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.**

Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, Seruga B, Amir E.

PLoS One. 2014 Feb 20;9(2):e88238. doi: 10.1371/journal.pone.0088238. eCollection 2014.